UK medicines manufacturing map exposes capacity gaps

UK medicines manufacturing map exposes capacity gaps

New analysis maps medicines manufacturing capacity across 31 UK sites. The BioIndustry Association identifies strengths in cell and gene therapies alongside missing domestic manufacturing options for two medicine categories.


The BioIndustry Association has mapped contract medicines manufacturing across 31 UK sites operated by 23 organisations, identifying substantial capability in cell and gene therapies alongside gaps in other medicine types. Its 2026 assessment distinguishes the manufacture of active substances from the formulation and filling of finished medicines, showing where developers may still depend on suppliers outside the UK.

The report draws on information supplied between May and September 2026 and covers good manufacturing practice, or GMP, production for human medicines. The participating organisations include commercial contract development and manufacturing organisations, NHS and university facilities and two research and technology organisations. It is a snapshot of documented capability, rather than an inventory of every plant that might be converted to manufacture a particular product.

The BIA approached 35 organisations. Of these, 23 were included, six had not responded by publication and six were excluded because their activities did not meet the report’s criteria, such as producing only research-grade material or waiting for a GMP licence. Organisations completed standard forms and the association queried unclear responses, but it did not independently audit every capability claim.

These reporting boundaries affect how the site totals can be interpreted. An organisation with the ability to manufacture a single batch a year is counted alongside a much larger producer, so the number of sites or companies is not a measure of available production volume. Nor does a facility’s ability to make clinical trial material necessarily demonstrate that it can manufacture the same product at routine commercial scale.

Cell and gene therapies represent the deepest reported area of UK capability. Nine organisations manufacture these therapies, and five report commercial-scale activity. The latter group includes two NHS organisations and the Cell and Gene Therapy Catapult, illustrating the role of public and collaborative facilities alongside private contract manufacturers. Across other advanced medicine categories, six organisations make RNA and eight report gene therapy manufacturing.

Drug substance is the active material that provides a medicine’s intended function, while drug product operations can involve formulation, sterile filling, packaging, labelling and release testing. A UK facility capable of putting imported material into finished containers does not necessarily have the synthesis, biological processing or purification systems required to manufacture the active substance.

Sixteen organisations in the survey can formulate, fill or finish medicines. Yet the BIA found no respondent manufacturing oligonucleotides to GMP standard in the UK. Five can undertake finishing operations for that category, meaning the active substance must come from elsewhere. Oligonucleotides are short nucleic acid sequences used in certain targeted treatments and require specialised synthesis, purification and quality control methods.

A second identified gap is live attenuated viral vaccines. None of the responding contract manufacturers reported producing them as a service, although five could undertake filling operations. The report does not mean that no UK organisation can ever make such a vaccine: it distinguishes contract manufacturing capability among the participating providers from production conducted internally by some vaccine developers.

Capacity for some established biological products is concentrated too. The survey identifies two sites offering commercial-scale manufacture of monoclonal antibodies and recombinant proteins: Fujifilm Biotechnologies in Billingham and Lonza in Slough. These products require tightly controlled biological processes, purification and quality assurance. The small number of identified commercial sites is therefore a relevant concentration risk, although the report does not quantify how much spare capacity either operator holds.

Clinical trial production often involves small quantities and extensive operator oversight, while later commercial manufacture requires processes that can be reproduced at greater scale. Moving towards commercial supply can require process transfer, validated larger-scale equipment and changes to testing and release arrangements. The BIA notes cooperation between specialist providers and public facilities to support these transitions.

The report identifies several regional clusters. Scotland accounts for six of the 31 UK sites, while London and the South East together account for eight. The Cell and Gene Therapy Catapult has manufacturing centres in Stevenage and Braintree in the East of England. No Cambridge site met the inclusion criteria in this survey, although the result describes this particular contract manufacturing dataset rather than the wider life sciences sector.

Additional capabilities are being developed. Sheffield’s Gene Therapy Innovation and Manufacturing Centre expects to obtain a GMP licence in 2027, according to the report, but it is not treated as already licensed capacity. The association intends to update its list as organisations achieve new manufacturing status and as existing respondents confirm changes.

In its policy recommendations, the BIA calls for easier access to manufacturing capital support, more suitable investment arrangements for smaller businesses, UK–EU mutual recognition of batch testing, competitive industrial energy costs and investment in specialist manufacturing skills. Its assessment provides an evidence base for those proposals while also showing where the UK would face constraints if it needed to increase production rapidly during a public health emergency.

The BIA intends to refresh the list as manufacturing organisations confirm changes in their capabilities and licensing status. Its initial snapshot identifies existing contract manufacturers and the categories for which developers currently have to seek production of active substances outside the surveyed UK network.


Stories for you


  • GM reportedly targets 20% more factory automation

    GM reportedly targets 20% more factory automation

    General Motors reportedly targets increased automation across North American factories. People familiar with the plans describe a 20% increase by 2028 and additional development of autonomous mobile robots for moving parts within production sites.


  • EU approves €57.6m for German semiconductor facilities

    EU approves €57.6m for German semiconductor facilities

    Germany has received approval for two semiconductor supply chain facilities. The €57.6m state aid package supports wafer dicing equipment production in Bochum and semiconductor precursor chemicals in Marburg; both sites remain planned.